The limitations of current viral and non-viral gene delivery technologies are well documented, but the solutions to challenges such as tolerability and moving beyond the liver remain elusive. David McCall, Senior Editor, Nucleic Acid Insights, talks to John Lewis, Founder and Chief Executive Officer of Entos Pharmaceuticals, about a novel nucleic acid delivery technology that seeks to harness the best of both worlds.
No takes yet. Share an insight, caveat, or question.
John W. Lewis (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: